325 related articles for article (PubMed ID: 35581440)
1. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
[TBL] [Abstract][Full Text] [Related]
2. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
[TBL] [Abstract][Full Text] [Related]
3. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
[TBL] [Abstract][Full Text] [Related]
4. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.
Fleisher AS; Pontecorvo MJ; Devous MD; Lu M; Arora AK; Truocchio SP; Aldea P; Flitter M; Locascio T; Devine M; Siderowf A; Beach TG; Montine TJ; Serrano GE; Curtis C; Perrin A; Salloway S; Daniel M; Wellman C; Joshi AD; Irwin DJ; Lowe VJ; Seeley WW; Ikonomovic MD; Masdeu JC; Kennedy I; Harris T; Navitsky M; Southekal S; Mintun MA;
JAMA Neurol; 2020 Jul; 77(7):829-839. PubMed ID: 32338734
[TBL] [Abstract][Full Text] [Related]
7. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
10. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
Lowe VJ; Lundt ES; Albertson SM; Przybelski SA; Senjem ML; Parisi JE; Kantarci K; Boeve B; Jones DT; Knopman D; Jack CR; Dickson DW; Petersen RC; Murray ME
Alzheimers Dement; 2019 Jul; 15(7):927-939. PubMed ID: 31175025
[TBL] [Abstract][Full Text] [Related]
11. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
[TBL] [Abstract][Full Text] [Related]
12. Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology.
Martersteck A; Ayala I; Ohm DT; Spencer C; Coventry C; Weintraub S; Bigio EH; Mesulam M-; Geula C; Rogalski E
Acta Neuropathol Commun; 2022 Aug; 10(1):111. PubMed ID: 35945628
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
14. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro S; Valeri A; Mazzon E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
[TBL] [Abstract][Full Text] [Related]
15. Diffuse Amyloid-β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques.
Abner EL; Neltner JH; Jicha GA; Patel E; Anderson SL; Wilcock DM; Van Eldik LJ; Nelson PT
J Alzheimers Dis; 2018; 64(4):1307-1324. PubMed ID: 30040735
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.
Sabbagh MN; Fleisher A; Chen K; Rogers J; Berk C; Reiman E; Pontecorvo M; Mintun M; Skovronsky D; Jacobson SA; Sue LI; Liebsack C; Charney AS; Cole L; Belden C; Beach TG
Arch Neurol; 2011 Nov; 68(11):1461-6. PubMed ID: 22084131
[TBL] [Abstract][Full Text] [Related]
17. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
[TBL] [Abstract][Full Text] [Related]
18. Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab.
Chiao P; Bedell BJ; Avants B; Zijdenbos AP; Grand'Maison M; O'Neill P; O'Gorman J; Chen T; Koeppe R
J Nucl Med; 2019 Jan; 60(1):100-106. PubMed ID: 29777003
[TBL] [Abstract][Full Text] [Related]
19. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
20. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
